MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

119.79 +1.35 (+1.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,030,205
Open 116.06
Bid (Size) 118.71 (1)
Ask (Size) 120.00 (1)
Prev. Close 118.44
Today's Range 114.02 - 121.91
52wk Range 86.08 - 124.61
Shares Outstanding 1,253,809,440
Dividend Yield 2.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
Via MarketMinute
Topics Intellectual Property
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026. 
Via Benzinga
Topics Earnings

Performance

YTD
+30.4%
+30.4%
1 Month
+7.8%
+7.8%
3 Month
+5.8%
+5.8%
6 Month
+15.5%
+15.5%
1 Year
+34.9%
+34.9%

More News

Read More
Gilead GILD Q3 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds
Via StockStory
Earnings Scheduled For October 30, 2025
Via Benzinga
Gilead Stock Ignites Retail-Trader Frenzy As Trodelvy Cuts Breast Cancer Progression Risk By 38% In Phase 3 Trial
Via Stocktwits
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?
Via Benzinga
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
From Gilead Sciences, Inc.
Via Business Wire
Meta Meltdown Sends Nasdaq Tumbling as Apple Shines After Hours
Via Chartmill
Topics Economy
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?
Via The Motley Fool
Topics Regulatory Compliance
Gilead Sciences Inc (NASDAQ:GILD) Reports Mixed Q3 2025 Results with Strong Earnings Beat and Cautious Revenue Outlook
Via Chartmill
Topics Earnings
Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations
Via StockStory
Covid Continues To Haunt Gilead. How One Drug Dinged Product Sales.
Via Investor's Business Daily
Gilead Sciences Announces Third Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
CVS Health Delivers Confident Outlook After Q3 Performance, Stock Hits 52-Week High
Via Benzinga
A Glimpse of Gilead Sciences's Earnings Potential
Via Benzinga
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Via Benzinga
Topics Economy
Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence
Market's Perilous Peak: Is the U.S. Stock Market More Overvalued Than Ever?
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
Retail Investors' Top Stocks With Earnings This Week: SoFi, Apple, Meta And More
Via Benzinga
3 Value Stocks We Approach with Caution
Via StockStory
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
From Gilead Sciences, Inc.
Via Business Wire
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
Via MarketMinute
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
Via MarketMinute
Topics Artificial Intelligence ETFs Economy

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 119.79
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 10/31/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 150.19B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 150B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story